Who Responds to Psilocybin Therapy: Evidence-Based Predictors

Psilocybin therapy response rates cluster between 60 and 70 percent across the major trials, with the remaining 30 to 40 percent showing partial response, no response, or in a small subset of cases, worse outcomes. Carhart-Harris et al. (2016, Lancet Psychiatry) reported 67 percent response at one week and 42 percent sustained response at three months in treatment-resistant depression. Understanding the difference between responders and non-responders is what separates honest expectation setting from retreat marketing. See also: psilocybin therapy preparation protocol.

Most public coverage of psilocybin therapy reports a headline number and stops there. The clinically useful question is not whether psilocybin works on average. It is who it works for, who it doesn't work for, and what predicts the difference. The research has converged on a small set of predictors that account for most of the variance, and the picture they paint is more specific than the marketing suggests.

What follows is what the response-predictor literature actually says, cross-checked against patterns observed across hundreds of integration sessions with founders, executives, and high-functioning professionals who came in after retreats. The pattern is consistent. The candidates who match the research predictors respond at rates well above the headline number. The candidates who do not match them respond at rates well below it. Treating psilocybin as a single intervention with a single response rate misses where the actual leverage is.

What Do Response Rates Actually Look Like Across the Major Trials?

Response rates vary substantially by trial, condition, dose, and follow-up window. Goodwin et al. (2022, NEJM) reported the COMP360 phase 2b trial of 233 participants with treatment-resistant depression, where the 25 mg dose produced a 36.7 percent response rate at week three, compared to 17.7 percent on the 10 mg dose and 18.0 percent on the 1 mg control. Carhart-Harris's 2016 open-label trial reported higher numbers, but with a smaller sample and no placebo control. Both findings are real. The gap between them is the design difference.

The honest summary is that the 60 to 70 percent figure often quoted comes from open-label or less stringent designs, while the more conservative double-blind randomized trials cluster closer to 35 to 50 percent on tight response definitions. The truth lives in between. What matters for a prospective participant is not the average. It is which side of the average their profile predicts they will land on. The predictors below are what move that probability.

Mystical Experience Intensity: The Primary Predictor

Mystical experience intensity correlates more strongly with psilocybin therapy outcome than any other single variable in the available literature. Roseman et al. (2018, Frontiers in Pharmacology) analyzed psilocybin trial data and reported correlations near r=0.6 between Mystical Experience Questionnaire scores and depression outcome at five weeks. That is a strong correlation in clinical research. It means roughly 36 percent of outcome variance is accounted for by the intensity of the mystical-type experience alone.

The mechanism is debated. One hypothesis is that mystical experience indexes the depth of default mode network disruption, which itself predicts the flexibility of post-session cognitive and affective reorganization. Another is that the experience produces a kind of perspective shift that reframes the relationship with symptoms in ways verbal therapy cannot. Either way, the empirical signal is clear. Sessions that produce high-intensity mystical experience are far more likely to produce clinical change than sessions that do not.

The Paradox of Pursuing Mystical Experience

The trap, and it is a real one, is that pursuing mystical experience as a goal often prevents it from occurring. The cognitive grip that produces the pursuit is precisely the grip the experience requires you to release. Participants who enter with the goal of "having a mystical experience" tend to either grasp at peak states that then collapse, or spend the session monitoring whether they are having one yet. Neither is the state the predictor describes.

The conditions that allow mystical experience to occur are the conditions the predictor research already names. Sufficient dose, prepared mindset, low resistance, surrender to the experience rather than control of it. Working backward from the goal does not work. Working on the conditions does. This is why preparation depth correlates with outcome: not because preparation causes mystical experience directly, but because preparation builds the conditions under which mystical experience becomes available.

Does Personality Openness Predict Psilocybin Response?

Yes, and with reasonable consistency across studies. Aday et al. 2021 reviewed the personality literature on psychedelic response and identified openness to experience, one of the Big Five traits, as a reliable predictor of both peak experience intensity and post-session integration outcome. Higher baseline openness is associated with greater willingness to engage with unusual perceptual content, less defensive resistance during the experience, and stronger follow-through on integration work afterward.

Conscientiousness shows mixed results across the literature. Some studies find it positively associated with integration adherence, others find no signal. Neuroticism, somewhat counterintuitively, does not appear to function as a strong negative predictor when baseline depression severity is controlled. The clinical implication is that openness, more than any other personality variable, tilts the response curve. Candidates who score high on this trait enter with a structural advantage. Candidates who score low can compensate, but they have to do work the high-openness candidates do not.

Whether Openness Can Be Trained

Interesting subquestion. Some evidence suggests that psilocybin sessions themselves increase trait openness, which is one of the rare cases where a psychiatric intervention produces a measurable personality change. But before the first session, can preparation build openness in candidates who score lower at baseline? The evidence here is thinner, but the practitioner observation is consistent: structured contemplative practice, somatic awareness work, and exposure to unfamiliar perceptual content during the preparation window appear to soften some of the resistance that low-openness candidates bring to the session.

This is part of why preparation depth correlates with outcome. It is not just about intention setting and medication review. It is partly about building the trait substrate the session will work with. Candidates who arrive having spent four weeks in this kind of work present differently in the dosing room than candidates who arrive after a stressful work month with no preparation. The biology is the same. The probability curve is not.

How Does Baseline Severity Predict Response?

Baseline depression severity in the moderate-to-severe range is associated with stronger response to psilocybin therapy than either mild depression or extremely treatment-resistant presentations. The Goodwin et al. (2022) COMP360 trial enrolled participants with treatment-resistant depression averaging baseline MADRS scores around 32, well into the severe range, and showed the largest effect in this band. Participants with mild depression frequently have less room for measurable improvement, while those with extremely long-standing treatment-resistant presentations show more variable response.

The clinical interpretation is that psilocybin appears to work best when there is significant pathology to address, the system has not been permanently shaped by decades of unsuccessful treatment, and the participant is motivated by sufficient suffering to engage seriously with preparation and integration. Mild depression often does not produce the engagement intensity required. Decades-long treatment resistance sometimes indicates structural features the substance cannot reach in a single or even multiple-dose protocol. The middle band is where the response curve is most favorable.

What Family History and Safety Factors Exclude Response?

Personal or family history of psychotic disorders or bipolar I disorder is an absolute exclusion in nearly all reputable clinical protocols. The risk of triggering a manic or psychotic episode in vulnerable individuals outweighs the expected therapeutic benefit, and both the MAPS and COMPASS screening criteria treat this as non-negotiable. This is not gatekeeping. It is straightforward risk management based on the case literature.

Active severe trauma without integration support, current substance use disorders, eating disorders in active phase, and recent suicidality also typically suggest psilocybin is not the appropriate intervention at this time. Cardiovascular conditions including uncontrolled hypertension warrant medical review because psilocybin produces modest transient blood pressure increases. None of these exclusions are permanent statements. They are sequence indicators. The right work in another modality may move someone from contraindicated to candidate over time. The reverse can also happen: a candidate today may become contraindicated tomorrow if conditions change.

"The candidates who match the research predictors respond at rates well above the headline number. The candidates who do not match them respond at rates well below it. The average is a fiction that hides where the real leverage is."

Does Therapeutic Alliance Predict Outcome?

Therapeutic alliance, the quality of the working relationship between participant and facilitator, predicts psilocybin therapy response in nearly every trial that has measured it. The Carhart-Harris group and others have reported that alliance scores during preparation correlate with both peak experience quality and integration outcomes, with effect sizes comparable to many other predictor variables. The mechanism is intuitive. A participant who trusts the facilitator surrenders more readily during the session. A participant who does not, holds on, and holding on prevents the state the predictor research describes.

This is where the retreat model and the clinical model diverge most sharply. Clinical protocols typically pair each participant with a dedicated therapist or therapist dyad across preparation, dosing, and integration. Retreats often place participants in groups of ten to thirty with facilitators they meet briefly before the ceremony begins. The first model builds alliance. The second model substitutes group setting and ritual context, which for some participants is adequate and for many is not. The data favors the dyad model when outcome is the metric. Read more on the post-session phase in psychedelic therapy for depression.

Integration Commitment as Maintenance Variable

Response at three months and beyond is predicted heavily by post-session integration work. The session produces a window. What you do in the four to twelve weeks after determines whether the window closes back to baseline or whether the new pattern stabilizes. Participants who commit to weekly integration work, whether with a practitioner, in a group, or through structured solo practice, show meaningfully better maintenance than those who treat the session as the intervention and the aftermath as optional. See psychedelic integration therapy for the full framework.

What Does Not Predict Psilocybin Response?

Several variables that intuition suggests should matter turn out not to predict response reliably in the controlled trial data. Age, gender, and prior psychedelic experience all show mixed or null effects across the major studies. The exception is that very advanced age may be associated with slightly lower peak experience intensity, but this does not translate cleanly into worse clinical outcomes. The candidate profile is less about demographic background and more about current psychological readiness, preparation depth, and the safety exclusions named above.

Prior psychedelic experience deserves a specific note because it surprises people. Veterans of recreational psychedelic use do not respond at higher rates than naive participants in the controlled trial data. The hypothesis is that recreational use builds familiarity but also sometimes builds patterns of cognitive control during the experience that work against the surrender state the predictor research describes. A first-time participant with a prepared, surrendered mindset often outperforms a veteran user who enters the room knowing how to manage the experience.

In the integration sessions I have seen across founder populations who came in after Ecuador, Mexico, and Netherlands retreats, the pattern matches the research. The responders are not the people with the most exotic psychedelic histories. They are the people whose preparation built somatic readiness and intention coherence, whose personality runs high on openness, whose baseline severity sat in the moderate-to-severe band, and who committed to integration work after. The non-responders, frequently, are people who treated the retreat as a single event, brought minimal preparation, and expected the substance to do the work alone. The substance does part of the work. The candidate does the rest. The split between responders and non-responders is mostly where the candidate did not show up. The related question of how to use the post-session window is covered in ego dissolution integration.

Frequently Asked Questions About Psilocybin Therapy Response